RESUMEN
BACKGROUND: The haemodynamic effects of intravenous infusion of the non-selective nitric oxide synthase (NOS) L-omega monomethyl arginine (L-NMMA) have previously been characterized in humans. Its effect of reducing cardiac index (CI) is an important reason for the increase in mortality in patients with septic shock receiving L-NMMA in a pivotal outcome trial for this indication. The mechanism for the reduction in CI however, is uncertain. METHODS: In this study, we investigated the haemodynamic and arterial stiffness response to a bolus intravenous infusion of L-NMMA (3 mg kg(-1) over 5 min) in 26 healthy human volunteers to clarify the likely cause of L-NMMA induced negative inotropic and chronotropic effects. Digital photoplethysmography (MicroMedical Pulse Trace) was used to derive two measures of arterial stiffness: stiffness index, a measure of large arterial stiffness, and reflection index (RI), a measure of small- to medium-sized arterial stiffness. Haemodynamic measurements of systolic blood pressure, diastolic blood pressure, heart rate, systemic vascular resistance index (SVRI), stroke index and CI were made using a bioimpedance monitor (BioZ Cardiodynamics). RESULTS: We found that changes in CI during L-NMMA are closely related to changes in RI and SVRI. CONCLUSION: The negative inotropic effect of L-NMMA may be a result of an increase in coronary vascular resistance and a resultant decrease in myocardial perfusion. The reduction in CI may also result from a direct reduction of the normal positive inotropic effect of NO by L-NMMA which is closely correlated with its effects on SVRI.
Asunto(s)
Arterias/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Contracción Miocárdica/efectos de los fármacos , omega-N-Metilarginina/farmacología , Adulto , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Femenino , Humanos , Masculino , Óxido Nítrico Sintasa/farmacología , Análisis de Regresión , Adulto JovenRESUMEN
The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia. This was a 14-week, open-label study including patients from 27 countries across the Middle East, Asia-Pacific, Africa and Latin America. Eight dosage strengths of single-pill amlodipine/atorvastatin (5/10, 10/10, 5/20, 10/20, 5/40, 10/40, 5/80 and 10/80 mg) were titrated to improve blood pressure and lipid control. Blood pressure and lipid goals were determined according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP ATP III) guidelines, respectively (blood pressure, <140/90 or <130/80 mm Hg; low-density lipoprotein cholesterol (LDL-C), <4.1 to <2.6 mmol l(-1) (<160 to <100 mgdl(-1))). Overall, 1649 patients received study medication. Most patients (91.4%) had >or=1 cardiovascular risk factor (as defined by NCEP ATP III guidelines) in addition to hypertension/dyslipidaemia, and 61.7% had coronary heart disease/risk equivalent. At baseline, mean blood pressure was 146.6/88.3 mm Hg and LDL-C was 3.4 mmol l(-1) (130.2 mgdl(-1)). At week 14, 55.2% of patients reached both blood pressure and lipid goals, 61.3% reached blood pressure goal and 87.1% reached lipid goal (34.0% were at lipid goal at baseline). Mean blood pressure reduction was 20.2/11.4 mm Hg. For patients who were lipid-lowering drug naive at baseline, mean reduction in LDL-C was 41.0%. Treatment-related adverse events led to the discontinuation of 3.6% of patients. Single-pill amlodipine/atorvastatin therapy was well tolerated and effective for the reduction of blood pressure and lipids to recommended goals in patients from diverse ethnic backgrounds.
Asunto(s)
Amlodipino/uso terapéutico , Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , LDL-Colesterol/sangre , Dislipidemias/tratamiento farmacológico , Ácidos Heptanoicos/uso terapéutico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Hipertensión/tratamiento farmacológico , Pirroles/uso terapéutico , Administración Oral , Anciano , Amlodipino/administración & dosificación , Amlodipino/efectos adversos , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Atorvastatina , Enfermedades Cardiovasculares/etnología , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Combinación de Medicamentos , Dislipidemias/sangre , Dislipidemias/complicaciones , Dislipidemias/etnología , Femenino , Ácidos Heptanoicos/administración & dosificación , Ácidos Heptanoicos/efectos adversos , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Hipertensión/complicaciones , Hipertensión/etnología , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Estudios Prospectivos , Pirroles/administración & dosificación , Pirroles/efectos adversos , Resultado del TratamientoRESUMEN
AIM: Angiotensin II type 2 (AT2) receptors are believed to become over-expressed in response to cardiovascular damage and to mediate beneficial effects (e.g. vasodilation). It is unknown whether AT2 receptors are functionally expressed in patients with insulin resistance (INSR). In this study, we investigated the role of the highly selective AT2 receptor antagonist, PD123319, on arterial stiffness and haemodynamic parameters in patients with INSR, compared with an age- and gender-matched control (N) group to determine whether there is functional expression of vascular AT2 receptors in patients with INSR. METHODS: We studied 10 subjects with INSR [mean age 28 +/- 5 years, body mass index (BMI) 30.4 +/- 5.4 kg/m(2), mean cholesterol level 4.7 +/- 0.7 mmol/l, mean homeostasis model assessment 2.78 +/- 0.84] and 10 age- and gender-matched normal subjects (mean age 27 +/- 7 years, BMI 23.6 +/- 2.5 kg/m(2), mean cholesterol level 3.9 +/- 0.6 mmol/l). All were normotensive, non-smokers and on no medications. Subjects received a 3-min infusion of PD123319 (10 microg/min). At the end of the infusion, arterial stiffness indices [stiffness index (SI) and reflective index (RI)] and haemodynamic parameters [cardiac index, systemic vascular resistance index (SVRI) and stroke index (ZI)] were measured. RESULTS: RI (mean % change: INSR 13.8 +/- 15.5%, N -0.2 +/- 4.6, p = 0.04) and SVRI (mean % change: INSR 13.5 +/- 9.7%, N -1.5 +/- 5.7, p = 0.005) increased significantly in response to PD123319 infusion in patients with INSR compared with controls. There were no significant changes in SI, systolic blood pressure, diastolic blood pressure and ZI. CONCLUSION: The results suggest the functional expression of AT2 receptors in small vessels that determine the inflection of the digital volume pulse wave in patients with INSR, possibly as an indicator of early vascular damage.
Asunto(s)
Arteriosclerosis/tratamiento farmacológico , Hemodinámica/efectos de los fármacos , Imidazoles/farmacología , Resistencia a la Insulina/fisiología , Piridinas/farmacología , Receptor de Angiotensina Tipo 2/metabolismo , Vasoconstrictores/farmacología , Adolescente , Adulto , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Humanos , Masculino , Persona de Mediana Edad , FotopletismografíaRESUMEN
OBJECTIVE: The objective of the study was to investigate the effects of cerivastatin therapy on forearm endothelial dependent acetylcholine (ACH) and independent (nitroprusside) vasodilator responses, blood pressure (BP) responses to intravenous infusions of angiotensin II (AII) and noradrenaline (NA) and on 24-h ambulatory BP recordings in type 2 diabetic men. DESIGN: Eleven type 2 diabetic men aged 59 +/- 9 years with total cholesterol levels of 5.0 +/- 1.26 mmol/l, triglycerides of 2.23 mmol/l and high-density lipoprotein cholesterol levels of 1.24 mmol/l completed a double-blind, randomized, crossover trial comparing 8 weeks of cerivastatin therapy (800 microg of nocte) with placebo. Forearm vascular resistance (FVR) responses to intrabrachial-arterial infusions of ACH (3-24 microg/min), nitroprusside (2-16 microg/min), the nitric oxide(NO) synthase inhibitor l-nitro-mono-methyl arginine (l-nmma) (8 micromol/min), ACH during l-NMMA infusion and BP responses to intravenous infusions of AII (12.5-50 ng/min) and NA (20-400 ng/min) were measured at the end of each treatment period. Twenty-four-hour ambulatory BP recordings were also performed. RESULTS: FVR responses to ACH during l-NMMA infusion were significantly (p = 0.026) greater during cerivastatin than during placebo therapy. In contrast, FVR responses to ACH in the absence of NO synthase inhibition did not differ significantly between cerivastatin and placebo therapies (p = 0.81). FVR increased by 31.4 +/- 57.3% in response to l-NMMA infusion during cerivastatin therapy compared with 6.1 +/- 41.2% during placebo therapy (p = 0.20). FVR responses to nitroprusside did not differ between cerivastatin and placebo therapies (p = 0.28), nor did BP responses to AII (systolic BP, p = 0.99; diastolic BP, p = 0.98) or NA (systolic BP, p = 0.21; diastolic BP, p = 0.48). Mean 24-h BP was similar during cerivastatin (123 +/- 10 or 70 +/- 7 mmHg) and placebo therapies (129 +/- 11 or 74 +/- 7 mmHg) (systolic BP, p = 0.26; diastolic BP, p = 0.41). CONCLUSION: Cerivastatin increases FVR responses to ACH in type 2 diabetic men with mild dyslipidaemia but only following NO synthase inhibition. This may indicate an improvement in endothelium-derived hyperpolarizing factor-mediated responses.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Piridinas/uso terapéutico , Resistencia Vascular/efectos de los fármacos , Acetilcolina , Anciano , Análisis de Varianza , Angiotensina II , Monitoreo Ambulatorio de la Presión Arterial , Estudios Cruzados , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/fisiopatología , Método Doble Ciego , Endotelio Vascular/efectos de los fármacos , Antebrazo/irrigación sanguínea , Humanos , Hiperlipidemias/complicaciones , Hiperlipidemias/tratamiento farmacológico , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Óxido Nítrico Sintasa/antagonistas & inhibidores , Nitroprusiato/uso terapéutico , Norepinefrina , Vasodilatadores , omega-N-MetilargininaRESUMEN
OBJECTIVE: To examine the effects of dietary isoflavone supplementation with an extract from red clover on cognitive function in postmenopausal women. DESIGN: Thirty postmenopausal women aged greater than 60 years received either two tablets of an extract of aglycone isoflavones from red clover (each containing formononetin 25 mg, biochanin 2.5 mg and less than 1 mg of daidzein and genistein) for 6 months in a randomized, controlled clinical trial. Cognitive function tests were performed at baseline and at the end of isoflavone or placebo therapy. RESULTS: Isoflavone supplementation was associated with an apparent improvement in block design (a test of visual-spatial intelligence) compared to placebo (isoflavone +12%, placebo -3%; p = 0.03), no improvement in verbal memory compared to an improvement on placebo (isoflavone +1%, placebo +29%; p = 0.023) and a deterioration in digit recall compared to placebo (isoflavone -6%, placebo +12%; p = 0.029). However, these findings were not statistically significant when corrections were made for potential chance findings due to multiple comparisons. CONCLUSION: Isoflavone supplementation does not appear to have major short-term effects on cognitive function in postmenopausal women. However, further clinical trials are required to determine whether small effects or long-term effects on cognitive function occur during isoflavone supplementation.
Asunto(s)
Cognición/efectos de los fármacos , Suplementos Dietéticos , Isoflavonas/uso terapéutico , Fitoterapia , Posmenopausia/fisiología , Trifolium , Cognición/fisiología , Inhibidores Enzimáticos/uso terapéutico , Estrógenos no Esteroides/uso terapéutico , Femenino , Genisteína/uso terapéutico , Humanos , Recuerdo Mental/efectos de los fármacos , Recuerdo Mental/fisiología , Persona de Mediana Edad , Pruebas Neuropsicológicas , Preparaciones de Plantas/uso terapéutico , Aprendizaje Verbal/efectos de los fármacos , Aprendizaje Verbal/fisiologíaRESUMEN
OBJECTIVE: The aim of this study was to determine whether dietary supplementation with isoflavones from red clover affected ambulatory blood pressure and forearm vascular endothelial function in postmenopausal type 2 diabetic women. DESIGN: Sixteen postmenopausal type 2 diabetics treated with diet or oral hypoglycaemic therapy completed a randomized double-blind crossover trial of dietary supplementation with isoflavones from red clover (approximately 50 mg/day) for 4 weeks compared to placebo. Twenty-four-hour ambulatory blood pressure recordings and forearm vascular responses to acetylcholine, nitroprusside and L-nitromonomethylarginine (L-NMMA) were measured at the end of each treatment period. RESULTS: Mean daytime systolic and diastolic blood pressures were significantly lower during isoflavone therapy compared to placebo (-8.0 +/- 3.4 and -4.3 +/- 1.9 mmHg respectively, p < 0.05). The increase in forearm vascular resistance following L-NMMA was significantly greater during isoflavone supplementation (20.9 +/- 6.5) than placebo (3.7 +/- 2.9 arbitrary units, p < 0.05), suggesting an improvement in basal endothelial function. Plasma lipoproteins, glycated haemoglobin and forearm vascular responses to acetylcholine and nitroprusside did not differ significantly between isoflavone and placebo therapy. CONCLUSION: Isoflavone supplementation from red clover may favourably influence blood pressure and endothelial function in postmenopausal type 2 diabetic women.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Isoflavonas/uso terapéutico , Fitoterapia/métodos , Extractos Vegetales/uso terapéutico , Trifolium , Anciano , Presión Sanguínea/efectos de los fármacos , Monitoreo Ambulatorio de la Presión Arterial , Estudios Cruzados , Diabetes Mellitus Tipo 2/fisiopatología , Método Doble Ciego , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/fisiopatología , Femenino , Antebrazo/irrigación sanguínea , Humanos , Persona de Mediana Edad , Posmenopausia , Resistencia Vascular/efectos de los fármacosRESUMEN
Blood pressure (BP) predictors of left ventricular mass index (LVMI) were studied in 40 healthy normotensive (71.4 +/- 4.4 years) and 31 hypertensive (73.5 +/- 4.8 years) elderly community-dwelling subjects using short-axis cardiac cine magnetic resonance imaging and 24-h ambulatory BP monitoring. Mean night-time BPs were calculated from the average of readings during sleep and mean daytime BPs were calculated from the remaining recordings. The hypertensive subjects were all receiving anti-hypertensive therapy with angiotensin-converting enzyme (ACE) inhibitors, calcium-channel blockers, beta-blockers or diuretics. Nocturnal systolic BP was a strong predictor of LVMI in both normotensive (beta = 0.38, p = 0.02) and treated hypertensive (beta = 0.39, p = 0.03) subjects. By contrast, daytime systolic BP was a weaker predictor of LVMI in the treated hypertensives (beta = 0.36, p = 0.04) and did not predict LVMI in the normal subjects (beta = 0.27, NS). Nocturnal BP may partly explain the increase in LVMI with ageing in subjects thought to be normotensive on the basis of daytime clinic BP recordings.
Asunto(s)
Monitoreo Ambulatorio de la Presión Arterial , Presión Sanguínea/fisiología , Ritmo Circadiano , Hipertrofia Ventricular Izquierda/diagnóstico , Anciano , Envejecimiento , Estudios de Casos y Controles , Femenino , Humanos , Hipertensión/patología , Hipertrofia Ventricular Izquierda/fisiopatología , Imagen por Resonancia Cinemagnética , Masculino , Factores de RiesgoRESUMEN
1. It has been hypothesized that the expression of angiotensin (Ang) II type 2 (AT(2)) receptors may become important in vascular disease; however, the functional existence of AT(2) receptors in normal adult humans remains to be established. 2. Vascular responses to AngII after the administration of the specific AT(2) receptor antagonist PD 123319 were determined in the forearm circulation of normal volunteers. 3. PD 123319 (8 microg/min) did not alter basal forearm blood flow, or forearm blood flow or forearm vascular resistance responses to AngII. 4. These results suggest that AT(2) receptors do not play a significant role in the regulation of forearm blood flow or forearm vascular resistance of normal volunteers, but do not preclude a role for AT(2) receptors in other vascular beds or in patients with cardiovascular disease.
Asunto(s)
Antebrazo/irrigación sanguínea , Receptores de Angiotensina/fisiología , Adulto , Angiotensina II/farmacología , Antagonistas de Receptores de Angiotensina , Estudios Cruzados , Método Doble Ciego , Humanos , Imidazoles/farmacología , Masculino , Piridinas/farmacología , Receptor de Angiotensina Tipo 2 , Flujo Sanguíneo Regional/efectos de los fármacos , Flujo Sanguíneo Regional/fisiología , Resistencia Vascular/efectos de los fármacosRESUMEN
OBJECTIVES: To assess the acceptability of the delivery of an isoflavone supplementation in the form of a powdered drink, and whether the supplementation of dietary isoflavones in this manner decreased the incidence of menopausal flushes. The secondary aims included assessment of other symptoms or parameters of estrogen deficiency and responses to isoflavones. METHODS: A randomized, double-blind, placebo-controlled, parallel-group trial comprising 24 postmenopausal women with symptoms of estrogen deficiency was performed over a 12-week period. The women were randomized to receive a dietary beverage containing isoflavones or an isoflavone-free, isocaloric placebo preparation. RESULTS: Although there was a high compliance rate among individual patients, there was a 25% withdrawal rate from the study in the active group. The incidence of complaints of bad taste tended to be higher in the active group (p = 0.07), and the total number of adverse events was significantly higher in this group (p < 0.001). There was no statistically significant difference in the incidence of flushes between the groups. There was no difference between the groups in Greene Menopause Symptom Scores, vaginal maturation value, levels of follicle stimulating hormone (FSH) or sex hormone-binding globulin (SHBG), or bone turnover markers. CONCLUSIONS: Powdered energy drinks are not commonly consumed in Australia and were poorly tolerated in this study. The high withdrawal rate and reporting of side-effects suggests that other methods of isoflavone delivery may be more appropriate in this culture, in future trials. At the dose used no benefit was seen in relief from menopausal symptoms, although for the sample size, the study could only have been expected to detect major differences between the groups.
Asunto(s)
Bebidas , Alimentos Formulados , Glycine max , Sofocos/tratamiento farmacológico , Sofocos/psicología , Isoflavonas/uso terapéutico , Menopausia/efectos de los fármacos , Menopausia/psicología , Aceptación de la Atención de Salud/psicología , Bebidas/análisis , Método Doble Ciego , Femenino , Hormona Folículo Estimulante/sangre , Alimentos Formulados/efectos adversos , Alimentos Formulados/análisis , Sofocos/sangre , Sofocos/clasificación , Sofocos/fisiopatología , Humanos , Isoflavonas/efectos adversos , Menopausia/fisiología , Persona de Mediana Edad , Polvos , Índice de Severidad de la Enfermedad , Globulina de Unión a Hormona Sexual/metabolismo , Glycine max/químicaRESUMEN
The relationship between alcohol consumption, blood pressure and left ventricular mass remains uncertain. A detailed alcohol intake history, clinic blood pressure measurements, 24-h ambulatory blood pressure recordings and measurements of left ventricular mass using magnetic resonance imaging (MRI) were performed in 98 males aged 47.9 +/- 9.7 years, 20 of whom were receiving antihypertensive monotherapy. Alcohol consumption (median intake 315 g/week, range 0-2050) was significantly related to supine systolic clinic blood pressures (beta = 0.20, p = 0.05) but not to clinic supine diastolic blood pressures (beta = 0.12, p = 0.25), 24-h blood pressures (systolic: beta = -0.03, p = 0.75; diastolic beta = -0.05, p = 0.60), awake blood pressures or sleeping blood pressures. Alcohol consumption was not related to left ventricular mass index (beta = -0.05, p = 0.59). Left ventricular mass was strongly related to mean 24-h systolic blood pressures (beta = 0.28, p = 0.01), mean awake and sleeping systolic blood pressures, and less strongly to clinic systolic blood pressures (beta = 0.23, p = 0.03). These results were not significantly altered by adjusting for age, smoking, body mass index or alcohol intake, or by excluding the 20 men who were receiving antihypertensive therapy. The results of this study suggest that alcohol consumption at levels commonly encountered in the community is not an important predictor of left ventricular mass index in men, either via direct effects or by indirect effects on blood pressure.
Asunto(s)
Consumo de Bebidas Alcohólicas/fisiopatología , Monitoreo Ambulatorio de la Presión Arterial , Hipertrofia Ventricular Izquierda/inducido químicamente , Adulto , Anciano , Consumo de Bebidas Alcohólicas/efectos adversos , Presión Sanguínea/efectos de los fármacos , Humanos , Hipertrofia Ventricular Izquierda/patología , Hipertrofia Ventricular Izquierda/fisiopatología , Modelos Lineales , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Encuestas y CuestionariosRESUMEN
Numerous studies have shown a relationship between alcohol intake and elevated clinic blood pressures (BP). However, there have been few studies on the relationship between alcohol consumption and 24-h ambulatory BP monitoring. This study aimed to determine the relationship between alcohol intake, clinic BP, and 24-h ambulatory BP recordings to determine to what extent a white coat effect may contribute to the relationship between alcohol consumption and BP. Clinical BP and 24-h ambulatory BP were measured in 121 male volunteers aged 50.6 +/- 9.8 years (range, 30-70 years) who consumed between 0 and 2050 g of alcohol per week (mean, 394 +/- 342 g; median, 385 g/week). Supine clinical systolic BP (SBP) was significantly related to alcohol intake (beta = 0.242; P = .007). Alcohol consumption was not related to 24-h mean SBP or diastolic BP (DBP), daytime SBP or DBP, or nighttime SBP or DBP (daytime SBP: beta = 0.02, P = .802). Alcohol intake was significantly related to the difference between clinic SBP and mean daytime SBP (beta = 0.260, P = .004). Twenty-four-hour mean heart rate (HR), daytime mean and nighttime mean HR were strongly associated with alcohol intake (24-h HR: beta = 0.455, P < .001). These results suggest that the association between alcohol consumption and elevated BP is contributed to by a significant white coat effect and that excessive alcohol consumption may be a significant factor in explaining differences between clinic and ambulatory BP measurements.
Asunto(s)
Consumo de Bebidas Alcohólicas , Determinación de la Presión Sanguínea/métodos , Presión Sanguínea/efectos de los fármacos , Visita a Consultorio Médico , Adulto , Anciano , Monitoreo Ambulatorio de la Presión Arterial , Ritmo Circadiano , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipertensión/inducido químicamente , Hipertensión/diagnóstico , Masculino , Persona de Mediana Edad , SístoleRESUMEN
The effects of dietary isoflavone supplementation using a purified extract of red clover containing approximately biochanin A 26 mg, formononetin 16 mg, daidzein 0.5 mg and genistein 1 mg per tablet at doses of one or two tablets per day were compared to placebo in a three-period, randomised, double blind, ascending dose study in 66 post menopausal women with plasma cholesterol levels between 5.0 and 9.0 mmol/l. Each treatment period lasted 4 weeks and a further nine women received placebo for the full 12-week period. All women consumed a low isoflavone diet for 2 weeks preceding the commencement of the study and for the 12-week study period. Urinary isoflavone excretion was very low in subjects receiving placebo but increased in a dose-dependent manner during therapy with one and two of isoflavone tablets. Dietary supplementation with isoflavones did not significantly alter total plasma cholesterol, LDL cholesterol, HDL cholesterol or plasma triglyceride levels. However, inverse correlations were found between urinary genistein excretion and plasma triglyceride levels and between urinary O-DMA excretion (an isoflavone metabolite) and plasma triglyceride levels in subjects receiving one isoflavone tablet, suggesting a weak relationship between isoflavone intake and plasma triglycerides which may be influenced by individual differences in isoflavone absorption or metabolism. The results suggest that isoflavone phytoestrogens from red clover in the proportions and quantities studied do not significantly alter plasma lipids in post menopausal women with moderately elevated plasma cholesterol levels.
Asunto(s)
Suplementos Dietéticos , Hipercolesterolemia/tratamiento farmacológico , Isoflavonas/administración & dosificación , Lipoproteínas HDL/efectos de los fármacos , Lipoproteínas LDL/efectos de los fármacos , Posmenopausia , Anciano , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Hipercolesterolemia/diagnóstico , Lipoproteínas HDL/sangre , Lipoproteínas LDL/sangre , Persona de Mediana Edad , Probabilidad , Valores de Referencia , Resultado del TratamientoRESUMEN
The effects of chronic oestrogen replacement therapy (ERT) (conjugated equine oestrogen 0.625 mg/day) and combined oestrogen and progestogen replacement therapy (HRT) (ERT plus continuous medroxyprogesterone acetate 5 mg/day) on 24-h ambulatory blood pressure recordings, forearm vascular resistance (FVR) and FVR responses to noradrenaline, angiotensin II, acetylcholine and nitroprusside were studied in 17 normotensive postmenopausal women in a 3-month randomized, double-blind, placebo-controlled crossover trial with 1 month of therapy in each treatment arm. During the last few days of each 1-month treatment period, the subjects underwent 24-h ambulatory blood pressure recordings and measurements of FVR responses. ERT and HRT reduced mean 24-h diastolic blood pressure by 4 and 5 mmHg, systolic blood pressure by 6 and 9 mmHg and mean 24-h heart rate by 5 and 3 beats/min, respectively for ERT and HRT (p < 0.05). Basal FVR was reduced by approximately 18% by ERT and HRT, but FVR responses to noradrenaline, angiotensin II, acetylcholine and nitroprusside were unaffected. ERT and HRT therapy for 1 month lowers blood pressure and basal FVR, but does not appear to influence FVR responses to acetylcholine, nitroprusside, noradrenaline and angiotensin II.
Asunto(s)
Monitoreo Ambulatorio de la Presión Arterial , Presión Sanguínea/efectos de los fármacos , Vasos Sanguíneos/fisiología , Terapia de Reemplazo de Estrógeno , Animales , Estudios Cruzados , Método Doble Ciego , Quimioterapia Combinada , Estrógenos/administración & dosificación , Estrógenos/uso terapéutico , Femenino , Antebrazo/irrigación sanguínea , Caballos , Humanos , Acetato de Medroxiprogesterona/uso terapéutico , Persona de Mediana Edad , Progestinas/uso terapéutico , Valores de Referencia , Resistencia Vascular/efectos de los fármacos , Vasoconstrictores/farmacología , Vasodilatadores/farmacologíaRESUMEN
OBJECTIVES: The effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with non-insulin dependent diabetes mellitus (type II diabetes) is uncertain. METHODS: The effects of estrogen replacement therapy (ERT, conjugated equine estrogen0.625mg orally daily), combined estrogen and continuous progestogen therapy (HRT, 0.625 mg of conjugated equine estrogens plus medroxyprogesterone acetate 5 mg daily) or placebo was compared in 20 postmenopausal type II diabetic women and 20 normal postmenopausal women in a double blind, randomised, crossover study. Patients receiving insulin were excluded from the study and all lipid modifying drugs were ceased at least 4 weeks prior to randomisation. Other medication including oral hypoglycaemics was kept constant for the duration of the study. RESULTS: Women with type II diabetes were a similar age (58.7+/-1.3 years) to the non-diabetic women (59.6+/-1.6 years) but they had a significantly greater body mass index, a higher incidence of treated hypertension, higher fasting plasma glucose levels, higher triglycerides and lower HDL cholesterol levels than non-diabetic women. ERT reduced total cholesterol and LDL cholesterol by a similar extent (8.9-12.3%) in normal and type II diabetic women and increased HDL cholesterol to a similar extent in both groups (11.0 and 8.9% respectively). ERT did not significantly alter fasting triglyceride levels in either group. The addition of medroxyprogesterone acetate 5 mg daily abolished the increase in HDL cholesterol associated with ERT in both groups but did not significantly affect any of the other lipid measurements. ERT and HRT did not significantly alter fasting insulin levels nor alter fasting glucose levels in either non-diabetic women or women with type II diabetes. CONCLUSIONS: ERT and HRT have similar effects on lipids in women with type II diabetes and non-diabetic women after 1 month of therapy.
Asunto(s)
Diabetes Mellitus Tipo 2/sangre , Estrógenos Conjugados (USP)/farmacología , Terapia de Reemplazo de Hormonas , Lípidos/sangre , Acetato de Medroxiprogesterona/farmacología , HDL-Colesterol/metabolismo , LDL-Colesterol/metabolismo , Enfermedad Coronaria/prevención & control , Estudios Cruzados , Método Doble Ciego , Femenino , Glucosa/metabolismo , Humanos , Insulina/metabolismo , Metabolismo de los Lípidos , Persona de Mediana Edad , Triglicéridos/metabolismoAsunto(s)
Sistema Cardiovascular/efectos de los fármacos , Hipoglucemiantes/farmacología , Canales de Potasio/fisiología , Compuestos de Sulfonilurea/farmacología , Adenosina Trifosfato/metabolismo , Animales , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/fisiopatología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Humanos , Hipoglucemiantes/uso terapéutico , Insulina/metabolismo , Secreción de Insulina , Islotes Pancreáticos/efectos de los fármacos , Canales de Potasio/efectos de los fármacos , Compuestos de Sulfonilurea/uso terapéuticoRESUMEN
BACKGROUND: Several recent studies have addressed issues including the optimum blood pressure target and differences between antihypertensive drug classes in reducing cardiovascular morbidity and mortality. OBJECTIVE: To review the results of several recent and topical hypertension trials. DISCUSSION: There is remaining uncertainty about the optimal blood pressure target with the exception of diabetics in whom aggressive blood pressure reduction has been shown to be more effective in reducing morbidity and mortality than less aggressive reduction. It remains unclear whether there are differences between antihypertensive drug classes in their ability to reduce cardiovascular events. At least two studies have demonstrated that it is possible to achieve good blood pressure control in the majority of hypertensive patients if two or more antihypertensive drugs are used.
Asunto(s)
Antihipertensivos/uso terapéutico , Hipertensión/tratamiento farmacológico , Anciano , Antihipertensivos/farmacología , Presión Sanguínea/efectos de los fármacos , Diabetes Mellitus Tipo 2/complicaciones , Quimioterapia Combinada , Cardiopatías/prevención & control , Humanos , Hipertensión/complicaciones , Hipertensión/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del TratamientoRESUMEN
BACKGROUND: ACE inhibitors are valuable and effective drugs in the treatment of hypertension, heart failure, myocardial infarction and nephropathy. Angiotensin receptor antagonists, which have recently been introduced into clinical practice, have the potential to replace ACE inhibitor therapy in many patients. OBJECTIVE: To review the mechanisms of action, indications and side effects of ACE inhibitors and angiotensin receptor antagonists and to highlight similarities and differences between the two drug classes. DISCUSSION: Angiotensin receptor antagonists have the theoretical advantage of being more effective in blocking the effects of angiotensin II at angiotensin type I receptors. The potential disadvantage of not potentiating bradykinin may be compensated by the unopposed action of angiotensin II on vascular angiotensin type II receptors, which appear to mediate similar beneficial cardiovascular effects to bradykinin. Angiotensin II receptor antagonists have a lower incidence of adverse effects than ACE inhibitors as they do not produce cough and appear much less likely to produce angioedema. Although ACE inhibitors are the most commonly prescribed antihypertensive drug class in Australia, they are underused for the treatment of heart failure and left ventricular dysfunction following myocardial infarction. Angiotensin receptor antagonists may become alternative therapies to ACE inhibitors in these disorders. However, at present they are only indicated for the treatment of hypertension.
Asunto(s)
Angiotensina I , Antagonistas de Receptores de Angiotensina , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Enfermedades Cardiovasculares/tratamiento farmacológico , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Antihipertensivos/farmacología , Toma de Decisiones , HumanosRESUMEN
AIMS: To determine the prevalence of isolated systolic hypertension (ISH) in patients 60 years of age and over attending general practitioners, and the proportion of patients in whom blood pressure (BP) remains within the ISH range when measured on three successive occasions and when using home BP monitoring. METHODS: BP was measured in 38 832 patients. Patients categorized as having ISH were reviewed after one week. Patients who had BPs in the ISH range at the second visit were provided with a home BP monitor and attended again in one week's time for further clinic blood pressure measurements. RESULTS: 8.6% of all patients were classified as having ISH and 31.4% as having borderline ISH at the first clinic visit. ISH was twice as prevalent in patients receiving antihypertensive therapy (12.4%) than in those not on antihypertensive therapy (6.2%). Of the patients initially categorized as having ISH, and who attended all three clinic visits and completed the home BP monitoring, 52.3% were confirmed as having ISH, 34.0% fell into the borderline ISH range and only 7.0% had a normal BP reading at the third clinic visit. The use of home BP monitoring produced similar results. CONCLUSION: ISH is present on first screening in approximately 8% of elderly Australian patients. This prevalence falls by about 50% when BP is measured on two further occasions, with most patients subsequently falling into the borderline ISH range. Home BP monitoring does not reduce the percentage of patients classified as having ISH on the basis of three clinic measurements.
Asunto(s)
Hipertensión/epidemiología , Factores de Edad , Anciano , Australia/epidemiología , Determinación de la Presión Sanguínea , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/diagnóstico , Hipertensión/etiología , Masculino , Tamizaje Masivo , Persona de Mediana Edad , Prevalencia , Autocuidado , Estrés Psicológico/complicaciones , Estrés Psicológico/fisiopatología , SístoleRESUMEN
OBJECTIVE: To compare the effects of chronic glibenclamide therapy and placebo on blood pressure and cardiovascular responsiveness in patients with non-insulin-dependent diabetes. DESIGN AND METHODS: Fourteen patients with non-insulin-dependent diabetes mellitus, seven of whom were receiving angiotensin converting enzyme inhibitor therapy, received glibenclamide or placebo for 1 month in a double-blind, randomized crossover study. At the end of each treatment period patients attended for studies of forearm vascular responsiveness to intra-brachial arterial infusions of angiotensin II, acetylcholine, sodium nitroprusside and noradrenaline, responses of blood pressure to intravenous infusions of noradrenaline and angiotensin II and 24 h ambulatory blood pressure monitoring. RESULTS: Administration of glibenclamide produced significantly better glycaemic control than placebo (fasting blood glucose level 8.5 +/- 2.4 versus 13.5 +/- 4.5 mmol/l, P < 0.001) and plasma insulin levels were significantly higher during glibenclamide treatment than they were with placebo (12.9 +/- 4.4 versus 9.2 +/- 4.1 mU/l, P < 0.05). Body weights at the ends of the glibenclamide treatment and placebo phases were similar (92.1 +/- 14.3 versus 91.1 +/- 14.3 kg, P = 0.085). Night-time systolic blood pressures were significantly higher during glibenclamide treatment than they were with placebo (128 +/- 17 versus 118 +/- 10 mmHg, P < 0.05) due to there being a smaller day-night difference in systolic blood pressure during glibenclamide treatment that appeared to occur mainly in patients receiving angiotensin converting enzyme inhibitors. Responses of diastolic blood pressure to intravenous infusion of angiotensin II and forearm vascular responses to intra-brachial arterial infusion of angiotensin II were significantly greater during glibenclamide treatment than they were with placebo (P < 0.05). However, the enhancement of forearm vascular responses during glibenclamide treatment appeared to be restricted to patients receiving angiotensin converting enzyme inhibitors. Responses of blood pressure to intravenous infusion of noradrenaline and forearm vascular responses to infusions of noradrenaline, acetylcholine and nitroprusside did not differ between glibenclamide treatment and placebo; neither did basal forearm vascular resistance. CONCLUSIONS: Glibenclamide therapy is associated with greater responses of blood pressure and forearm vascular responses to infusion of angiotensin and higher nocturnal blood pressures. This effect appears to be influenced by concomitant angiotensin converting enzyme inhibition.